Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551608 | 1.00 | FOLH1 (0.45) | FOLH1TGM2MMEECE1ACE | |
| SCHEMBL30502374 | 0.94 | FOLH1 (0.40) | FOLH1TGM2MMEECE1ACE | |
| SCHEMBL16695025 | 0.92 | MME (0.44) | TGM2MMEECE1ACEPNMT | |
| SCHEMBL22804047 | 0.92 | MME (0.44) | TGM2MMEECE1ACEPNMT | |
| SCHEMBL2537174 | 0.92 | MME (0.44) | TGM2MMEECE1ACEPNMT | |
| SCHEMBL30940317 | 0.91 | SIRT2 (0.43) | TGM2ACEPNMT | |
| SCHEMBL1420538 | 0.90 | CASP1 (0.46) | MMEECE1PNMT | |
| SCHEMBL30904667 | 0.90 | CASP1 (0.46) | MMEECE1PNMT | |
| SCHEMBL30122530 | 0.90 | CASP1 (0.46) | MMEECE1PNMT | |
| SCHEMBL2544343 | 0.90 | CASP1 (0.46) | MMEECE1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800876-A | Fmoc-O-tert-butyl-L-glutamic acid production method | 浙江汉诺化工科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | claimed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | claimed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | claimed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | claimed |
| CN-117800876-B | Fmoc-O-tert-butyl-L-glutamic acid production method | 浙江汉诺化工科技有限公司 | 2025-11-14 | — | — | CN | disclosed |
| CN-120118195-A | Phage lyase analogues and uses thereof | 上海多米瑞生物技术有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-117800876-A | Fmoc-O-tert-butyl-L-glutamic acid production method | 浙江汉诺化工科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117800876-A | Fmoc-O-tert-butyl-L-glutamic acid production method | 浙江汉诺化工科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116970042-A | Antiviral polypeptide analogues | 上海多米瑞生物技术有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2019241903-A1 | SYNTHETIC METHOD OF BIVALIRUNDIN | SHANGHAI SPACE PEPTIDES PHARMACEUTICAL CO., LTD. (CN) | 2019-12-26 | — | — | WO | disclosed |
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Ashvattha Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-9526794-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2016-12-27 | — | — | US | disclosed |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | NATIONAL INSTITUTES OF HEALTH (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2552458-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | Wayne State University (US) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123591-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | WAYNE STATE UNIVERSITY (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170028075-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | PAM, UACA, FLT1 | FOLH1 3470/4885TGM2 537/4885MME 4177/4885 |
| US-20130136697-A1 | INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES | UACA, PAM, JAK3 | FOLH1 2813/4885TGM2 821/4885MME 4232/4885 |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | PAM, UACA, FLT1 | FOLH1 3470/4885TGM2 537/4885MME 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.